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REVIEW
The paradigm of norgestimate: a third-generation testosterone-derivative progestin 
with a peripheral anti-androgenic activity and the lowest risk of venous 
thromboembolism
Giovanni Grandi , Maria Chiara Del Savio and Fabio Facchinetti
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero- 
Universitaria Di Modena, Modena, Italy
ABSTRACT
Introduction: Norgestimate (NGM) is a testosterone derivative with peculiar receptor activities.
Areas covered: This is a narrative review of the available data on the pharmacotherapy of NGM in 
combined hormonal contraceptives (CHCs) in terms of contraceptive efficacy, venous thromboembo-
lism (VTE) risk, safety, tolerability and bleeding patterns. A comprehensive literature review was 
conducted in August 2020 using PubMed with the keyword ‘norgestimate’.
Expert Opinion: NGM shows a mild estrogenic activity associated with anti-mineralocorticoid and anti- 
androgenic properties, largely responsible for the cardiovascular safety profile. The anti-androgenic 
property depends on the androgen receptor (AR) nuclear translocation (AR trafficking and its sub-
nuclear distribution), the inhibition of 5α-reductase activity (it possesses higher activity compared to 
other available progestins), and the increase on sexual hormone binding globulin (SHBG) levels if 
combined with an estrogenic counterpart. NGM is one of the molecules that best modulates the 
power of ethinyl-estradiol on the thromboembolic risk, being associated with the lowest VTE risk 
between different CHCs. NGM has the advantage of retaining peripheral anti-androgenic activity, 
demonstrated by the impact on lipid and glucose metabolism, and it should be preferred if compared 
with other similar progestins of the same class of risk which are much more androgenic, such as 
levonorgestrel.
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The choice of the most suitable progestin for a woman’s needs 
plays a crucial role in assuring good compliance toward hor-
monal contraception. The synthetic progestins available are 
generally divided into progesterone and testosterone deriva-
tives, and an analog of spironolactone [1,2]. The common 
ability of the different ‘progestational’ steroids is to bind to 
the progesterone receptor (PR), with high or low affinity, 
guaranteeing the secretory maturation of a previously estro-
gen-modified proliferative endometrium. On the other hand, 
the main differences between different available progestins 
are due to their pharmacological, pharmacokinetic and phar-
macodynamic properties, and to their different abilities to 
work on other intracellular steroid receptors. The various pro-
gestins are characterized by different affinity to the estrogen 
(ER), androgen (AR), glucocorticoid (GR) and mineralocorticoid 
(MR) receptors, expressing their possible agonist or antagonist 
actions [3]. Such interactions may either induce transactivation 
or prevent activation of the different steroid receptors and 
may be responsible for some positive or for some of the 
undesirable side effects of progestins. In other words, even if 
they belong to the same ‘progestin family’, they can show 
a completely different clinical profile [4]. Different generations 
of progestins have followed one another, and new molecules 
are and will be put on the market; nevertheless, some older 
molecules continue to maintain peculiar advantages in this 
continuous evolutionary process [5]. In this wide panorama, 
norgestimate (NGM) represents a particular progestin, as it is 
a testosterone derivative with a peculiar receptor activity. The 
aim of this narrative review is to focus on the main advantages 
of NGM, related in particular to its unique peripheral anti- 
androgenic activity, the biological explanation of its low 
thrombotic risk and its reassuring tolerability and safety, nearly 
30 years after its first release on the hormonal contraception 
market.
2. Materials and methods
This narrative review paper includes selected pharmacother-
apy data of interest about the progestin NGM, in particular 
contained in combined hormonal contraceptive (CHC) oral 
formulations in combination with ethinyl-estradiol (EE), in 
monophasic or multiphasic association, published in English 
up to July 2020. The research was carried out in August 2020 
and the databases were searched from 1 January 1977 to 
31 July 2020. Relevant documents were identified through 
a literature search in PubMed using the keyword 
‘norgestimate’.
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We recovered and evaluated all potentially relevant articles 
and checked their reference lists to identify any additional 
relevant publications. Only papers in the English language in 
press or just published were considered. We did not consider 
abstracts and/or case reports. All identified references were 
reviewed by a second author (MC.DS).
The initial search retrieved 407 documents. Studies that 
were not relevant to the outcomes of interest of the review 
or duplicates were not considered. The final reference list 
consisted of 74 papers. The data are presented in a narrative 
structure, divided into paragraphs for each subtopic.
3. Chemistry
NGM (Figure 1a) is a 19-nortestosterone derivative of the 
gonane family [1]. NGM is 17-ethylinated, 18-methyl steroid 
with a 17-position acetate and an oxime at position 3 (Figure 
1a). The C-17 acetate group as well as a unique C-3 oxime 
group inhibit its ability to bind to ARs. Because the C-3-keto 
group is typical of androgenic compounds, its replacement by 
the oxime group can contribute to reduce the androgenicity 
of NGM as compared with norgestrel (NGL) and levonorgestrel 
(LNG) [6], in addition to other peripheral mechanisms that will 
be reported later.
4. Pharmacokinetics and metabolism
NGM is considered a prohormone or a prodrug. Through 
a rapid hydrolysis of the acetate at position 17, it forms 17- 
deacetyl-norgestimate (norelgestromin, NGMN) (Figure 1b), 
which carries most of the progestational activities of NGM, 
being its major metabolite [7]. A low concentration of NGMN 
can be detected in the blood for about 5 hours after 250 µg 
NGM oral assumption, with a mean peak of 100 pg/mL, com-
pared with a mean peak concentration of NGM of 3,500 pg/mL 
after 1.5 hours [6]. On the other hand, the half-life of NGMN 
exceeds 24 hours, due to the protection of oxime group from 
further rapid metabolism [6] (Table 1). Other metabolic trans-
formations include cleavage at the oxime, ketone reduction at 
position 3, A + D ring hydroxylation and reduction of the C4- 
C5 double bond. By final conjugation, it goes to glucuronide 
or sulfate metabolites. The last step includes that a small 




5.1.1. Effect on progesterone receptor (PR)
NGM and its metabolites have a similar progestational activity 
to that of progesterone (P) molecule itself on the endometrium 
(as shown by its strong binding affinity for PRs in the uterus of 
the rabbit [9]) (Figure 2a). Highly progestational responses to 
NGM have been demonstrated in many experimental models. 
Another parameter used to describe a typical progestational 
activity is the suppression of ovulation. In rabbits, oral doses of 
NGM have been shown to inhibit ovulation by blocking the 
preovulatory surge of luteinizing hormone (LH) [10]. In addition, 
NGM replacement permits pregnancy continuation despite the 
absence of endogenous P in ovariectomized rats. In estrogen 
primed immature rabbits, endometrial stimulation follows both 
oral and subcutaneous administration of NGM: the maintained 
potency of NGM after subcutaneous administration can indicate 
that its progestational activity does not depend on first-pass 
hepatic metabolism [9].NGM and NGMN are PR partial agonists, 
Article highlights
● Norgestimate shows a mild estrogenic activity associated with anti- 
mineralocorticoid and anti-androgenic properties, largely responsible 
for the cardiovascular safety profile.
● The anti-mineralocorticoid activity of norgestimate is clinically impor-
tant, reducing the classical side effects of CHCs such as bloating and 
water retention and decreasing the risk of hypertension during their 
use.
● The anti-androgenic activity of norgestimate is complex, depending 
on the androgen receptor trafficking and its subnuclear distribution, 
the peripheral inhibition of 5α-reductase activity and the important 
increase of SHBG levels.
● Norgestimate is one of the progestins that best modulate the power 
of ethinyl-estradiol on the thromboembolic risk, being associated 
with the lowest venous thromboembolism risk between different 
CHCs.
● Norgestimate, having the advantage of keeping retaining peripheral 
anti-androgenic activity, should be preferred if compared with other 
similar progestins of the same class of risk which are much more 
androgenic, such as levonorgestrel.
Figure 1. A) Molecular structure of norgestimate (NGM) and b) of principal metabolites of NGM: norelgestromin (NGMN) and levonorgestrel (LNG).
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with half-maximal effective concentration (EC50) values of 13 
and 11.1 nM, respectively; these concentrations fall within the 
total serum concentration of NGM and its metabolite after oral 
administration (10−9-10−7 M) [11].
In humans, the ovulation inhibition dose in quantity 
per day per os for NGM is 200 µg, while its transformation 
dose per cycle is 7 mg, resulting in a uterotrophic index of 
2.9% [2].
5.2. Estrogenic activity
5.2.1. Effect on estrogen receptor (ER)
Inhibition of estrogenic activity by NGM has also been 
demonstrated experimentally. In ovariectomized rats, cor-
nification of the vagina induced by estrone is inhibited by 
oral and subcutaneous administration of NGM [10]. 
However, in contrast to its anti-estrogenic properties, 
NGM has been found to be virtually inactive in a series 
of estrogenic test systems. Thus, the anti-estrogenic prop-
erties are rather a progestin-mediated action, as opposed 
to direct interference with the interaction between estro-
gen and its receptor. Indeed, ER activity has been demon-
strated, in particular selective agonism at ERα (EC50 30.4 
and 43.4 nM for NGM and NGMN), while NGM and its 
metabolite are not active on ERβ [11].
Table 1. Pharmacokinetic parameters of norgestimate (NGM) and its metabolite 
norelgestromin (NGMN).
NGM NGMN
Long terminal half-life 45–71 hours >24 hours
Peak plasma concentration 30 minutes 1.5 hours
Figure 2. A) Relative binding affinities of common used progestins to progesterone receptor (PR). natural progesterone is the reference (1). b) Relative binding 
affinities of common used progestins to androgen receptor (AR). dihydrotestosterone is the reference (1). the assay measures displacement of 3H R5020 from the PR 
isolated from the uterus of the rabbit. data from reference [9].
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5.3. Mineralocorticoid activity
5.3.1. Effect on mineralocorticoid receptors (MR)
Though the relative binding affinities of NGM to MR has 
been initially described as null [2], in subsequent experi-
ments, its affinity for MR was described as moderate, i.e. 
a half maximal inhibitory concentration (IC50) of 81.2 and 
83.7 nM [11]. The half-maximal inhibition (Ki) of 1 nM 
aldosterone binding to MR occurred at 232 ± 53.3 nM of 
NGM, 140 ± 32.1 nM of NGMN and 4 ± 0.49 nM of spir-
onolactone (Figure 3). This NGM anti-mineralocorticoid 
activity may be clinically important, i.e. by reducing water 
and sodium retention and decreasing the risk of hyperten-
sion and cardiovascular disease during its use.
5.4. Glucocorticoid activity
5.4.1. Effect on glucocorticoid receptor (GR)
The relative binding affinity of NGM to GR is negligible, as is 
the potential agonist/antagonist activity on this type of steroid 
receptor [2]. Similarly, NGM has been found to be clinically 
inactive on GR. Its affinity for GR is very low (IC50 of 325 and 
255 nM) [11].
5.5. Androgenic activity
The androgenic or anti-androgenic activity of NGM is not only 
based on AR direct bond but depends on other receptor and 
peripheral effects, such as AR nuclear translocation (AR traf-
ficking and its subnuclear distribution), effect on 5α-reductase 
activity and on sex hormone-binding globulin (SHBG) levels if 
combined with an estrogenic counterpart. These different 
activities confer NGM with some clinical anti-androgenic 
effects, despite its direct derivation from testosterone and 
possible partial transformation into a mild androgenic mole-
cule such as LNG (Figure 4).
5.5.1. Effect on androgen receptors (AR)
5.5.1.1. Receptor affinity. The knowledge about NGM bind-
ing to the AR and thereby inducing androgenic or anti- 
androgenic effects is based mainly on animal experiments. 
NGM has essentially minimal activity on AR. This has been 
proven by its very weak affinity for AR in rats [around 1.3% 
times that of dihydrotestosterone (DHT)] (Figure 2b) [12].In 
these same assays its two principal metabolites, NGMN and 
LNG, were proven to be more androgenic than NGM, which 
makes it unlikely that they made any significant contribution 
to the biologic activity of NGM [13].
An ideal progestin should achieve a progestational 
response when given at a low concentration and it has to 
elicit an androgenic response only at a high concentration. In 
Figure 3. Antagonistic mineralocorticoid activity of norgestimate (NGM) and 
norelgestromin (NGMN), in comparison to spironolactone. data adjusted from 
reference [11].
Figure 4. Antiandrogenic activities of norgestimate (NGM) in combination with EE. T: testosterone. DHT: dihydrotestosterone. SHBG: sex hormone-binding globulin. 
AR: androgen receptor. EE: ethinylestradiol. NGM: norgestimate.
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AR binding assays, only very high concentrations of NGM (IC50 
of 764 nM) displaced radiolabeled DHT, the androgen stan-
dard. In PR binding assays, the NGM’s IC50 was only 3.5 nM, 
with a relative binding affinity of 1.24. NGM androgen-to- 
progestin receptor binding ratio was 219, indicating a highly 
selective progestational response, higher than P itself. The 
descending order of selectivity of different progestin is indeed 
NGM, P and LNG [14]. The partial AR agonist activities of NGM 
and NGMN seem even higher than that of cyproterone acetate 
(CPA). However, NGM and NGMN (10−6 M) induced luciferase 
activity of up to 70% of that observed with a synthetic andro-
gen agonist (10−9 M), in comparison to 50% for CPA (10−6 
M) [15].
5.5.1.2. AR trafficking and its subnuclear distribution. 
After androgen binding to the ligand-binding domain of AR, 
the AR-androgen complex moves into the nucleus where it 
can interact with target DNA sequences. The complex can 
then induce the recruitment of downstream transcription fac-
tors and the subsequent transcription of target genes [16].
Anti-androgens can affect each step of the molecular action 
of androgens. It was demonstrated that NGM permits green 
fluorescent protein AR transport into the nucleus, but less 
efficiently than with natural ligands. In a cell line well-known 
as a useful tool for studying androgen and anti-androgen 
actions, it was observed in competitive studies that the half- 
maximal inhibition (Ki) of NGM (4.2 + 0.561078 M) was close to 
that of cyproterone acetate (CPA) (6.6 + 0.861078 M), which is 
the gold standard for hyperandrogenism treatment. If we 
consider the dosage of NGM and its intracellular concentration 
in target tissue, this Ki is compatible with a biological effect of 
NGM on AR. Moreover, these data show that NGM and NGMN 
decreased AR transcriptional activity (24%), although less effi-
ciently than that observed with CPA at the same concentration 
(47%) (Figure 4) [15].
5.5.1.3. Effect on 5α-reductase activity. Increased 5α- 
dihydrotestosterone (DHT) concentration due to elevated per-
ipheral androgen metabolism is very important in the pathogen-
esis of acne, hirsutism and androgenic alopecia. The clinical 
manifestations of hyperandrogenism, such as hirsutism and 
acne, are disturbing to most patients and it can be associated 
with other conditions, including polycystic ovary syndrome 
(PCOS), insulin resistance and cardiovascular diseases risk [17]. 
In many androgen-responsive organs, such as skin, androgenic 
activity is elicited mainly by DHT [18]. The reduction of testos-
terone to DHT is catalyzed by the 5α reductase enzyme, that can 
exist in two isoforms, which differ pH requirement and in 
Michaelis-Menten constants [19]. Both isoenzymes are simulta-
neously present in many tissues including the central nervous 
system, the respiratory, urogenital and gastrointestinal tract, the 
skin and the endocrine system [20]. Finasteride, a potent 5α- 
reductase type 2 inhibitor, suppressed circulating DHT beyond 
70% and led to improvements in women suffering from hirsut-
ism and acne. The effect of other progestins on the inhibition of 
5α-reductase is variable. In an in vitro model using breast skin, 
NGM showed 50% inhibition of 5α-reductase at a concentration 
of 10 pM, in the range of finasteride activity (IC50 of 1 pM) 
(Figure 5) [21]. These results provide evidence for the usefulness 
of NGM for the treatment of hirsutism and male-pattern bald-
ness in women. In the same study, LNG, dienogest (DNG), CPA 
and gestodene (GSD) had IC50 values between 52 and 98 pM. 
Out of all progestins tested, only CPA and NGM have been 
reported to inhibit skin 5α-reductase activity. On the other 
hand, the EE component does not influence 5α-reductase activ-
ity (Figure 5). In genital skin tissue, estradiol (E2) has been shown 
to inhibit 5α-reductase only at high concentrations, suggesting 
that estrogens appear not to be a major factor influencing 5α- 
reductase activity.
5.5.1.4. Effect on sex hormone-binding globulin (SHBG) 
levels. SHBG is a carrier protein produced by the liver. Its 
production has been demonstrated to be highly estrogen 
sensitive. Oral intake of EE alone results in an important dose- 
dependent increase in SHBG levels. Progestins administration 
results in varying degrees of SHBG decrease, depending on 
both the dose and type of molecule used, which could be 
interpreted as an expression of differences in the anti- 
estrogenic potency of the progestin. Therefore, the combined 
effect on SHBG could be used as a measure of the total 
estrogenic effect of EE and the anti-estrogenic effect of the 
progestin, or the total estrogenicity of the combination. This 
Figure 5. Progestins inhibit skin 5α-reductase activity in vitro. The most potent inhibitor in comparison to finasteride was norgestimate, followed by levonorgestrel, 
dienogest, cyproterone acetate, gestodene, norgestrel, norethisterone and 3-keto-desogestrel. No effect was seen with ethinyl estradiol. Data from reference [21].
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marker changes have been even proposed to predict the risk 
of venous thromboembolism (VTE) during CHC use [22].
Moreover, the elevations in SHBG can effectively reduce the 
amount of bioactive T and decreasing its potential androgenic 
activity. A strongly androgenic progestin can inhibit this action 
by competitively displacing T from SHBG and allowing freer 
active T to produce its effects.
The increase in SHBG in users of CHCs containing NGM is 
particularly evident in monophasic associations (+167% and 
+161%), +163%, +69% and +126% in triphasic formulations, 
significantly lower than with other anti-androgenic progestins 
such as drospirenone (DRSP) (+270%), DNG (+269%) and CPA 
(+325% and +402%), but higher than with second-generation 
androgenic progestins such as LNG (+50-60%) (Figure 2b) [23]. 
In in vitro studies of human SHBG, both NGM and NGMN, 
showed little affinity for SHBG, as they were unable to displace 
T from SHBG even at concentrations >10,000 nM (Figure 
6)[24].
6. Coagulatory effect of CHCs containing NGM
6.1. Effect of the estrogenic component
EE-containing CHCs can normally increase the activity of some 
coagulation factors by about 30 to 50% [factors I (fibrinogen), 
II, VII, VIII, IX, X and XI], with a contemporary decrease of the 
activity of naturally occurring anticoagulants, like protein S by 
approximately 30 to 40% [25]. The acquired hypercoagulability 
seems to be independent of the route of administration of EE 
[26], but directly dependent on its dose [27,28]. Substitution of 
EE by oral E2, as performed in the last 10 years, may reduce 
but not abolish the coagulation stimulus of CHCs [29], though 
the transdermal/vaginal route of administration would be 
more neutral in comparison to the oral one [30].
6.2. Effect of the progestin component
As reported above, different progestins may differently inter-
act with PR, ER, GR, MR and AR, exerting either agonistic or 
antagonistic effects. Three effects may be relevant to the 
effect of a progestin molecule on coagulation: glucocorticoid, 
anti-mineralocorticoid and androgenic activity, but in the end, 
the latter are the most relevant in clinical practice.
6.2.1. Due to glucocorticoid activity
Activation of GR increases the effect of thrombin and, to 
a lesser extent, enhances procoagulation factors [31]. Several 
progestins may bind and activate GR [32], but at the doses 
used in vivo only medroxyprogesterone acetate (MPA) can 
exert some glucocorticoid-mediated procoagulant effects 
[33]. As reported, the activity of NGM on GR is not clinically 
relevant.
6.2.2. Due to mineralocorticoid activity
Activation of the renin-angiotensin-aldosterone system 
increases blood coagulation though several mechanisms, 
including elevation of plasminogen activator inhibitor-1, 
which inhibits fibrinolysis, and platelet adhesiveness [34], 
which is antagonized by aldosterone [35]. Traditionally, 
besides P, the progestins norethisterone acetate (NETA), GSD 
and mostly DRSP can have some anti-mineralocorticoid prop-
erties [2]. However, recent evidences also suggest a mild anti- 
mineralocorticoid activity for NGM in vitro [11] (Figure 3), 
which could be clinically relevant regarding the specific VTE 
risk of this progestin.
6.2.3. Due to androgenic activity
The androgenic action of progestins has different coagulatory 
functions. It counteracts, in a dose- and potency-dependent 
way, the estrogen-induced reduction of activated protein 
C (APC) and of tissue factor pathway inhibitor and the induced 
increase in factor VIIa. It does not counteract the estrogen- 
induced increase in fibrinogen and the decrease in antithrom-
bin III [36–38]. Accordingly, androgenic progestins, to 
a greater extent than other progestins, antagonize the estro-
gen-induced activation of the coagulation system. For this 
reason, the activation of coagulation is less pronounced with 
more androgenic CHCs, at a similar EE dose. The most potent 
androgenic progestins are first and second-generation proges-
tins, such as NETA, NGL and LNG [39,40]. Following the admin-
istration of 250 µg NGM, systemic exposure to LNG should be 
theoretically about a third that observed in a pill containing 
150 µg LNG (20–25% of 250 µg = 50–62.5 µg), provided it is 
Figure 6. Relative binding affinity of different progestins for human sex hormone-binding globulin (SHBG) measured as displacement of ‘H-testosterone. data from 
reference [24].
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clinically relevant [41]. Indeed, 250 µg dose of NGM counter-
acts the 30 µg EE-induced increase in SHBG less than a 150 µg 
LNG dose (see above). Accordingly, in theory the combination 
of EE with NMG is less androgenic than that with LNG, and its 
use should be associated with a slightly higher risk of VTE: 
however, this is not confirmed by epidemiological data.
6.3. VTE risk during CHCs containing NGM
As we will see, epidemiological data are largely supported by 
the reported biological data. The risk of VTE is lower with pills 
containing more androgenic progestins such as LNG in com-
bination with EE. The data show that LNG does not relevantly 
decrease the risk of VTE induced by 50 µg EE, but it counter-
acts, in part, the effect of the 30 µg EE doses. The same 
counteraction can be observed with 100 µg LNG added to 
20 µg EE [42]. NGM is partially metabolized to LNG (20–25%), 
and, at the doses administered, it exposes the user to levels of 
LNG like those achieved with the administration of 50 µg LNG. 
It seems that this exposure is sufficient to reduce the risk of 
VTE induced by EE, at levels similar to those observed with 
a CHC containing LNG [42].
According to a recent Danish historical registry-based 
cohort study, in the group of progestins in combination with 
30–40 μg EE, NGM shows a similar VTE risk of LNG and NETA 
(1.18 95% CI 0.86–1.62), while other progestins in combination 
with the same EE dose show a significantly doubled risk 
between 2.09 and 2.24, i.e. desogestrel (DSG), GSD, DRSP 
and CPA. In comparison with non-users, this risk with ≥30 µg 
EE + NGM is still lower than with products containing 20 μg EE 
in combination with GSD, DSG or DRSP (2.56 vs. 3.26 to 4.84) 
[43]. NGM is the progestin that, associated with EE, has shown 
the lowest risk of VTE (5–7 cases for 10.000 women users/year) 
according to the European Medicines Agency, together with 
first- and second-generation progestins such as NETA and LNG 
[44] (Table 5). Interestingly, the risk of its principal metabolite, 
NGMN, is considered slightly higher (6–12 cases for 10,000 
women users/year), probably for the most used and studied 
route of administration (transdermal) that is associated with 
higher cumulative serum doses of EE (Table 2) [45].
7. Contraceptive efficacy
NGM are available combined to EE in two different formula-
tions: a monophasic (days 1 to 21, 35 μg of EE/250 μg of NGM) 
and a triphasic preparation (days 1 to 7, 35 μg of EE/180 μg of 
NGM; days 8 to 14, 35 μg of EE/215 μg of NGM; days 15 to 21, 
35 μg of EE/250 μg of NGM). The triphasic combination has 
the rationale to permit a lower total dose of NGM in compar-
ison with the monophasic one without an increase of break-
through bleeding (BTB) occurrence. In general, no significant 
difference in contraceptive efficacy has been demonstrated 
among all the various mono and triphasic formulations 
(Table 3).
An open-label, noncomparative clinical trial conducted in 
Germany with 59,701 women enrolled showed an overall Pearl 
Index (PI) of 0.25 (95% CI: 0.19 to 0.31) [46]. The contraceptive 
efficacy was demonstrated also by two smaller multicenter 
trials conducted in Austria and in Germany, respectively on 
97 and 147 women, with no pregnancies occurring during the 
entire follow-up period [47,48]. An excellent contraceptive 
efficacy (overall and theoretical PI of 0.55 and 0.37, respec-
tively) was achieved also with the triphasic EE/NGM combina-
tion during a 12-month open, non-comparative study on 661 
women [49].
These formulations have proved to be equally effective as 
the other contraceptive combinations commonly used. Two 
multicenter, double-blinded, randomized clinical trials 
Table 2. Risk of developing a blood clot (VTE) in a year according to European medicines agency [44]. 1: further studies are ongoing or planned to collect sufficient 
data to estimate the risk for these products. CHC: combined hormonal contraceptive.
Risk of developing a blood clot (VTE) in a year
Women not using a combined hormonal pill/patch/ring and are not pregnant About 2 out of 10,000 women
Women using a CHC containing levonorgestrel, norethisterone or norgestimate About 5–7 out of 10,000 women
Women using a CHC containing etonogestrel or norelgestromin About 6–12 out of 10,000 women
Women using a CHC containing drospirenone, gestodene or desogestrel About 9–12 out of 10,000 women
Women using a CHC containing dienogest About 8–11 out of 10,000 women
Women using a CHC containing chlormadinone or nomegestrol in combination with estradiol1 Not yet known
Table 3. Experimental process of ethinylestradiol/norgestimate (EE/NGM) in a monophasic or triphasic formulation in relation to its contraceptive efficacy. X: study 
without a comparator. PI: Pearl index. GSD: gestodene. NGL: norgestrel, LNG: levonorgestrel.
Outcomes Sample size Country Comparator Design PI Reference
Contraceptive efficacy N = 59,701 Germany X Monophasic, non comparative 0.25 Runnebeaum [46]
N = 97 Austria X Monophasic, non comparative 0 Huber [47]
N = 147 Germany X Monophasic, non comparative 0 Becker [48]
N = 189 Italy GSD Monophasic, comparative 0 Affinito [60]




N = 661 France X Triphasic, non comparative 0.55 Gauthier [49]
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conducted in Unites States (US) on 1,473 women comparing 
the monophasic EE/NGM combination with monophasic EE/ 
NGL showed no statistically significant differences between 
the two formulations with respect to pregnancy rates [50]. 
The same results have been achieved in an open-label, com-
parative clinical trial of triphasic EE/NGM versus triphasic EE/ 
LNG conducted on 4,234 women [51] (Table 3).
8. Impact on lipids and glucose metabolism
Lipid levels are biomarkers of cardiovascular risk, even if it is 
not clear whether CHC-induced changes of lipid metabolism 
can be really translated into clinically significant effects on this 
risk. Past studies have shown that users of high-dose CHCs 
experienced a marked increase in total cholesterol and trigly-
cerides levels. With the evolution of CHCs, the gradual reduc-
tion of the EE doses has reduced their impact on lipid 
metabolism.
The impact of CHC on lipoprotein levels changes depend-
ing on the potency of the estrogen and its counteraction by 
the androgenic potency of the progestin [52]. In general, the 
EE stimulus causes a positive effect, with a decrease of LDL 
and an increase of HDL and triglycerides [53]. Progestins with 
androgenic properties antagonized these EE effects, in a dose- 
related fashion, with an increase in LDL and a decrease of HDL 
and triglycerides levels. Accordingly, at similar EE doses, CHCs 
with less androgenic/anti-androgenic molecules, such third- 
generation progestins as NGM, have shown greater increases 
in HDL than other formulation containing more androgenic 
progestins, such as LNG-based CHCs.
This effect was confirmed for NGM in clinical trials, both for 
the comparisons with second-generation (LNG and NGL) and 
other third-generation progestins: Chapdelaine et al. reported 
that serum levels of HDL were significantly increased from 
baseline values in the EE/NGM group but were significantly 
decreased in the EE/NGL group. Increases in LDL levels were 
moderate in the EE/NGM group but were pronounced in the 
EE/NGL group, resulting in a significant difference between 
formulations in the impact on LDL/HDL ratio, a common mar-
ker of arterial risk [54]. A German study showed essentially no 
change in cholesterol from baseline after six cycles of use 
during EE/NGM treatment, also in subjects with higher basal 
cholesterol levels [46]. Another US randomized controlled trial 
comparing monophasic NGM and NGL and showed that HDL 
levels were constantly elevated in the NGM group and 
depressed in the NGL group, and that EE/NGL significantly 
increased levels of LDL. For this reason, the LDL/HDL ratio 
decreased by 7.7% in the NGM group while it increased by 
18.5% in the NGL group [50] (Figure 7).
In the comparison between EE/NGM and EE/GSD, there was 
no significant difference between formulations with regard to 
the influence on any measured cholesterol parameter. 
A similar significant increase was observed in the plasma levels 
of HDL-cholesterol levels. In contrast, the LDL-cholesterol 
levels were significantly decreased. These changes in lipid 
metabolism appear to reflect a predominance of the effect 
of the estrogen component in combination with an anti- 
androgenic progestin, in particular for NGM [55].
CHCs have also been associated with subclinical distur-
bances in carbohydrate metabolism. They can include 
impaired glucose tolerance and increased insulin resistance, 
which are known risk factors for type 2 diabetes mellitus. Both 
the estrogen and progestin components of CHC may be 
responsible for inducing insulin resistance [56].
Traditionally, it was proposed that high-dose (50 μg EE) and 
high androgenic progestin containing CHCs have a more pro-
nounced negative effect on glucose metabolism when compared 
to lower doses preparations. In general, a progestin with high 
androgenic activity has been shown to cause a greater decline in 
insulin sensitivity (SI) compared to a progestin with an anti- 
androgenic activity. Indeed, pills containing second-generation 
progestins, such as LNG, can normally decrease SI [57].
The EE/NGM combination caused an increase of mean 
fasting glucose of only 0.1% at cycle 12 and of 2.3% at cycle 
Figure 7. Percentage change from baseline in serum lipids and lipoproteins: all users of monophasic EE/NGM and EE/NG. EE: ethinyl-estradiol. NGM: norgestimate. 
NGL: norgestrel *: Two-sided t-test significant at the 5% level. modified from reference [50].
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24 in comparison to a significant increase of 1% at cycle 12 
and 4.6% at cycle 24 for EE/NGL group [50]. This evidence to 
date would suggest that NGM formulations have little or no 
effects on carbohydrate metabolism in studies conducted in 
up to 24 cycles of use.
9. Safety and tolerability
9.1. Body weight
Body weight did not change significantly during the use of EE/ 
NGM in clinical trials and withdrawal rates for weight gain are 
very low, constantly below 2% of users (Table 4). In a study 
conducted by Runnenbaum et al. [46], the body weight of the 
women enrolled increased by only 0.6% at cycle 6. The same 
trend was achieved by Huber [47] in a dual center trial on an 
EE/NGM monophasic formulation. Discontinuation because of 
weight gain during monophasic EE/NGM versus EE/NGL was 
observed in two different clinical trials: both samples demon-
strated a slightly higher rate of discontinuation with NGL 
(1.4% with EE/NGL versus 1% with EE/NGM, by Corson [50]; 
1.54% versus 0.84%, by Andolsek [58]). There were no signifi-
cant changes in body weight at the end of 6 cycles in 
a comparative study by Tantbirojn et al. (EE/LNG vs. EE/NGM) 
[59] and of a comparative study by Affinito et al. between EE/ 
GSD and EE/NGM formulations [60]. The triphasic formulation 
EE/NGM showed the same moderate effects on body weight 
[49], with a similar effect in comparison with EE/LNG [61].
9.2. Blood pressure
None the studies analyzed found any clinically significant 
changes in ambulatory blood pressure in the subjects during 
monophasic EE/NGM treatment [47,50,59–61]. The same trend 
was observed with the triphasic formulation [49,61]. All these 
data seem to support the clinical anti-mineralocorticoid activ-
ity of progestin in decreasing the risk of hypertension, despite 
the concomitant presence of ≥ 30 µg of EE than can lead to 
a mild increase in blood pressure [62]. However, no included 
study was based on more accurate Holter 24-h ambulatory 
blood pressure measurements, as more recent trials have 
performed for other contraceptive formulations [63].
9.3. Acne
The treatment with EE/NGM was shown to be effective on 
mild to moderate acne vulgaris, reducing the lesions count 
from the beginning of the treatment cycle to the end [13,64]. 
Jaisamrarn et al. [65] conducted an investigator-blinded, ran-
domized, parallel-group trial at three centers in Thailand to 
compare the effectiveness and the safety of triphasic EE/NGM 
and biphasic EE/DSG. The efficacy and safety parameters 
Table 4. Experimental process of ethinylestradiol/norgestimate (EE/NGM) in a monophasic or triphasic formulation in relation to its safety and tolerability. X: study 
without a comparator. GSD: gestodene. NGL: norgestrel, LNG: levonorgestrel.
Outcomes Sample size Country Comparator Design Withdrawal rates for weight gain Reference
Safety and tolerability N = 59,701 Germany X Monophasic, non comparative / Runnebeaum [46]
N = 97 Austria X Monophasic, non comparative 1% Huber [47]
N = 147 Germany X Monophasic, non comparative 0 Becker [48]
N = 1473 United States NGL Monophasic, comparative EE/NGM 1% 
EE/NGL 1.4%
Corson [50]
N = 140 Thailand LNG Monophasic, comparative 0 Tantbirojn [59]
N = 189 Italy GSD Monophasic, comparative / Affinito [60]
N = 1783 United States X Triphasic, non comparative / Andolsek [58]
N = 661 France X Triphasic, non comparative 0.16% Gauthier [49]
N = 66 LNG Triphasic, comparative 0 Janaud [61]
Table 5. Experimental process of ethinylestradiol/norgestimate (EE/NGM) in a monophasic or triphasic formulation in relation to its bleeding pattern. X: study 
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including body weight, body mass index, vital signs, acne 
lesions count, facial sebum output, adverse events and con-
comitant medication were recorded. The total lesions count 
continuously decreased throughout the 6 months of treat-
ment in both groups compared to baseline: the relative 
decrease from baseline to cycle 6 in the mean percentage of 
total lesions count in EE/NGM and EE/DSG was 74% and 65%, 
respectively, with a non-statistically significant mean differ-
ence of 9%. Regarding facial seborrhea, treatment with EE/ 
NGM showed greater improvement compared to baseline 
than EE/DSG after 6 months of treatment (p = 0.005). The 
response to treatment was evaluated by the investigators as 
‘excellent’ or ‘good’ for 87% of subjects in the EE/NGM group 
and for 74% in the EE/DSG group. In the subjects’ self- 
assessment, those treated with EE/DSG (96%) showed 
a similar improvement to EE/NGM (93%). In conclusion, this 
study demonstrated that the effects of EE/NGM and EE/DSG 
on total acne lesions count are similar, but EE/NGM has a more 
beneficial effect on facial seborrhea.
Efficacy on facial acne was also demonstrated in a non- 
comparative study by Runnenbaum et al. [46] investigating 
the monophasic EE/NGM association: the incidence of acne 
was reduced from 12% during the pretherapy cycle to 9% 
after six cycles of EE/NGM treatment. In another trial, acne 
was cited as the reason for withdrawal by 0.8% of subjects 
using EE/NGM compared with 1.2% of those using EE/ 
NGL [54].
9.4. Adverse effects
The occurrence of adverse effects during EE/NGM is similar to 
that reported with other CHCs. The percentage of women who 
experienced nausea or headache at the end of six cycles of 
treatment was lower than the percentage with these symp-
toms before treatment with EE/NGM, decreasing, respectively, 
from 6% to 4% and from 13% to 5% [46]. Affinito et al. [60] 
compared the adverse reaction during EE/NGM in comparison 
to EE/GSD in the monophasic formulation: the safety profile 
was good for both contraceptives, but patients in the EE/NGM 
group reported a higher incidence of breast pain, whereas 
patients in the EE/GSD group experienced a higher incidence 
of headache (with no statistically significant differences). The 
primary reason for discontinuation were adverse reactions in 
3% of women in the EE/GSD group (persistent abdominal and 
gastric pain, insomnia, vasomotor syndrome, tachycardia) and 
in 2% in the EE/NGM group (varicose veins, mastodynia, ver-
tigo, headache). The most common adverse events during the 
study by Tantbirojn et al. [59] were dizziness, nausea, and 
headache: the only statistically significant differences obtained 
were for headache and dizziness, finding more prevalent in 
the EE/LNG group in comparison of the EE/NGM group.
10. Bleeding patterns
In CHCs users, cycle control is crucial for compliance, which in 
turn is the major determinant of use-effectiveness. 
Runnenbaum et al. [46] demonstrated the excellent cycle 
control exercised by the monophasic formulation of EE/NGM. 
The incidence of breakthrough (BTB) and intermenstrual 
spotting decreased after the therapy, from 4.5% to 3% and 
from 9% to 4% after six cycles of EE/NGM treatment, respec-
tively. The occurrence of amenorrhea was only 1.4% of the 
women in cycle 6. Almost all (97%) women reported an 
absence of irregular bleeding by the end of cycle 6. 
Reductions in cycle length and duration of bleeding by 4% 
and 16%, respectively, was noted and 32% of the women 
experienced a reduction in intensity of bleeding. In the com-
parative study by Corson [50] on monophasic formulation EE/ 
NGM versus EE/NGL, the daily incidence of BTB and spotting 
was similar with the two treatment regimens. Amenorrhea was 
reported more frequently by subjects treated with EE/NGL 
than by those treated with EE/NGM. The difference between 
the two groups in the reporting of failure to have withdrawal 
bleeding was statistically significant (0.7% for EE/NGM versus 
1.5% for EE/NGL, p < 0.001). Tantbirojn et al. [59] compared 
the cycle control of monophasic formulation of EE/LNG with 
the EE/NGM one: the formulation with LNG appeared to pro-
vide better cycle control than NGM one, but without statistical 
significance. No differences in the mean cycle length of both 
groups were observed, as well no significant differences in 
amount of withdrawal bleeding. The mean duration of the 
bleeding in the EE/NGM group was longer than in the EE/ 
LNG group with a significant difference. Affinito et al. [60] 
compared the monophasic EE/NGM formulation with the EE/ 
GSD one: the majority of cycles, 94.4% in the EE/GSD group 
and 92.8% in the EE/NGM group, were normal. BTB occurred in 
0.2% of cycles in the EE/GSD group and 1.6% of cycles in the 
NGM group; the frequency of spotting was 5.4% in the EE/GSD 
group and 5.6% in the EE/NGM group. Similar results were 
achieved with the triphasic formulation of EE/NGM. Gauthier 
et al. [49] demonstrated a decrease in the occurrence of severe 
flow from 14.8% before the study to 4% after cycle 12. Also, 
BTB and amenorrheic cycles decreased from 12.1% during 
cycle 1 to 2.6% at the end of the evaluation and from 4.1% 
to 3.7%, respectively. The same trend for a positive impact on 
cycle control was observed by Andolsek [58] in two multi-
center non-comparative studies on the EE/NGM triphasic for-
mulation conducted in the US. The incidence of scheduled 
withdrawal bleeding in EE/NGM was constantly higher than 
95%, as demonstrated in Table 5.
11. Conclusions
The results from this narrative review try to biologically 
explain many of the advantages found with the use of NGM 
in the clinical practice as a hormonal contraceptive. The com-
bination of EE with NGM, both in monophasic and in triphasic 
regimens, represents a valid therapeutic ally in many 
situations.
The receptor activity of this progestin is particularly effec-
tive and well-balanced. The highly selective progestational 
response in relation to the androgenic one, higher than that 
of natural P itself, confers to this molecule an intrinsic proges-
tational activity demonstrated in many experimental models 
and by the extremely low dose of ovulation inhibition 
(200 µg), among the lowest between the progestins we com-
monly use. Through rapid hydrolysis, NGM forms NGMN, 
which carries most of the progestational activities of the 
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parent compound, while only about 20–25% is finally meta-
bolized to LNG.
The mild estrogenic activity of the molecule mainly 
expresses itself on type α ER; ERα and ERβ have different 
downstream transcriptional actions, resulting in specific tissue- 
specific biological activities. ERα is highly expressed in the 
uterus, ovarian theca cells, mammary gland and liver. Indeed, 
ERβ is highly present in ovarian granulosa cells, bone marrow 
and brain. There are some common physiological roles for the 
two ERs, in particular in the development and function of the 
ovaries, and in the protection of the cardiovascular system. 
The α subtype exerts its more prominent role in the uterus 
and the breast, as well as in the preservation of skeletal home-
ostasis [66].
NGM is also devoid of any relevant GR activity, which is 
harmful to the skeletal and cardiovascular system, like other 
modern progestins. The most interesting receptor activities of 
NGM, however, are the anti-mineralocorticoid and the anti- 
androgenic ones. As shown, these properties are also largely 
responsible for the cardiovascular safety profile of the mole-
cule, both on the arterial and on the venous side. The first 
property is clinically important, reducing the classical side 
effects of CHCs such as bloating and water retention and 
decreasing the risk of hypertension during their use. 
Moreover, it can show a positive effect in women suffering 
from premenstrual syndrome up to premenstrual dysphoric 
disorder [67]. The second property is more complex for NGM: 
it depends on other receptor and peripheral effects, such as 
the AR nuclear translocation (AR trafficking and its subnuclear 
distribution), the inhibition of 5α-reductase activity (it pos-
sesses higher activity compared to other available progestins), 
and the increase on SHBG levels if combined with an estro-
genic counterpart (Table 5). This anti-androgenic activity is 
invaluable when we have to manage particular diseases such 
as PCOS or signs of hyperandrogenism such as acne, hirsutism 
and androgenic alopecia, as demonstrated by the use in clin-
ical practice for the treatment of such conditions [68]. It is no 
coincidence that the excellent receptor activity of this hormo-
nal contraceptive translates into high acceptability of patients 
in real-life use, among the highest among the various CHCs 
available [69].
This receptor activity, in particular the anti-androgenic and 
the anti-mineralocorticoid one, is extremely important also for 
the safety profile of NGM. This progestin is one of the mole-
cules that best modulate the power of EE on the thromboem-
bolic risk and that are associated with the lowest VTE risk 
between different CHCs. However, NGM has the advantage 
of keeping retaining peripheral anti-androgenic activity, 
demonstrated by the impact on lipid and glucose metabolism, 
and it should be preferred if compared with other similar 
progestins of the same class which are much more andro-
genic, such as LNG [61] and NETA.
On the contrary, the most important limitation of this 
molecule is that it is still used in oral contraceptives only 
with synthetic estrogens such as EE, even at medium-high 
dosages (up to 35 µg). In the last years, the market of CHCs 
has been evolving toward a reduction of EE dose and more 
metabolically neutral estrogens such as E2 [29] and estetrol 
(E4) [70] and toward products that will be able to administer 
these weaker estrogens by non-oral ways of administration 
[30]. NGM would probably not be suitable for use in these 
formulations that require progestins with a more uterotropic 
effect (such as DNG, nomegestrol acetate or nestorone) [29], 
as NETA and DSG were not, mainly for the not satisfactory 
cycle control [71,72]. However, NGM’s main metabolite 
(NGMN), has been and will be an excellent component of 
transdermal patch CHC, in combination with EE [45].
Despite this, we believe that contraceptive formulations 
containing NGM occupy and will maintain an important role 
in combined hormonal contraception, despite the fact that 
30 years have already passed since the first release of this 
progestin onto the market.
We have to report some limitations to the performance of 
this review. The most important of them is its narrative design: 
despite including a systematic review process of the literature, 
this study tends to be mainly descriptive and thereby often 
focuses on a subset of studies in an area chosen based on 
availability or author selection. Thus, this narrative review, 
while informative, can often include an element of selection 
bias and it is likely to overstate its health benefits and to 
underestimate its negative effects. For these reasons, these 
conclusions should be taken with caution and confirmed in 
future investigations.
12. Expert opinion
During the whole reproductive lifespan, women need safe hormo-
nal contraceptives, with the sole purpose of avoiding unintended 
pregnancies. The most important and relevant adverse effect, 
fortunately rare, that could happen during CHC use is the occur-
rence of VTE. This effect can naturally occur without the use of any 
CHC (2 women per 10,000 women/year) and even more during 
pregnancy and especially the puerperium period (up to 350 
women per 10,000 women/year) [73]. During modern CHC use, 
this risk can vary between 5 and 12 women per 10,000 women/ 
year. Statements from the EMA include that ‘products that contain 
LNG, NETA and NGM are associated with the lowest risk of VTE. The 
decision to use any other product than one known to have the 
lowest risk should be taken only after a discussion with the woman 
to ensure she understands the risk of VTE with CHCs, how her 
current risk factors influence this risk, and that her VTE risk is 
highest in the first ever year of use’. Although these recommenda-
tions are not always followed in clinical practice by physicians [74] 
and may tend to limit the correct customization of hormonal 
contraceptives, they cannot be forgotten. For this reason, there 
are molecules such as LNG and NGM (NETA is no longer readily 
available), which will always play an important role in hormonal 
contraception technology. Furthermore, NGM has undeniable 
advantages over LNG, which we have summarized in this review, 
the first of them being of a generation beyond (third vs. second). 
LNG is a much more androgenic molecule, presenting no anti- 
mineralocorticoid activity, and these effects, from a therapeutic 
point of view, can only overshadow it. The pros of EE/NGM combi-
nations (both mono and triphasic) include the satisfactory use in 
the woman with water retention and bloating or with premenstr-
ual syndrome or in the woman with signs of hyperandrogenism, 
such as hirsutism and acne, or PCOS, for which they could be 
proposed as first choices between different CHCs. All these 
EXPERT REVIEW OF CLINICAL PHARMACOLOGY 11
features are associated with very high contraceptive efficacy and 
excellent cycle control, which are fundamental requirements for 
a treatment that, besides being safe, must make the woman who 
uses it feel good.
There will never be a ‘pill’ for all women and neither is this the 
case with this combination; having many products allows us to 
customize the best treatment for a specific woman, always keeping 
in mind what other therapeutic effects we want to obtain from this 
wonderful tool that, almost 60 years after its introduction, has gone 
very far beyond family planning.
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